Why the study?
Does silencing miR-208a with an antagomir prevent doxorubicin-induced myocyte apoptosis and cardiac dysfunction in eight-week-old female Balb/C mice?
Does silencing miR-208a with an antagomir prevent doxorubicin-induced myocyte apoptosis and cardiac dysfunction in eight-week-old female Balb/C mice?
Silencing miR-208a represents a potential therapeutic strategy to prevent doxorubicin-induced cardiotoxicity by preserving GATA4 and reducing myocyte apoptosis.
Answers are grounded in this paper and cite their sources.
May attenuate doxorubicin cardiotoxicity in mice; leaves open clinical translation of antagomir therapy.
AIMS: GATA4 depletion is a distinct mechanism by which doxorubicin leads to cardiomyocyte apoptosis, and preservation of GATA4 mitigates doxorubicin induced myocyte apoptosis and cardiac dysfunction. We investigated a novel approach of attenuating doxorubicin induced cardiac toxicity by silencing miR-208a, a heart specific microRNA known to target GATA4. METHODS AND RESULTS: Eight-week-old female Balb/C mice were randomly assigned to sham, antagomir, and control groups. Antagomir group were pretreated with miR-208a antagomir 4 days before doxorubicin administration. At day 0, control and antagomir groups received 20 mg/kg of doxorubicin, while sham mice received phosphate buffered solution. Echocardiography was done at day 7, after which animals were sacrificed and hearts harvested and assessed for apoptosis and expression of miR-208a, GATA4, and BCL-2. Doxorubicin significantly upregulated miR-208a, downregulated GATA4, and increased myocyte apoptosis, with resulting decrease in cardiac function. In contrast, therapeutic silencing of miR-208a salvaged GATA4 and BCL-2 and decreased apoptosis, with improvement in cardiac function. CONCLUSION: Doxorubicin upregulates miR-208a and promotes cardiomyocyte apoptosis, while therapeutic silencing of miR-208a attenuates doxorubicin induced myocyte apoptosis with subsequent improvement in cardiac function. These novel results highlight the therapeutic potential of targeting miR-208a to prevent doxorubicin cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Tony et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: